Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 11/20 | 0.87 |
| ▸ | RARB | P10826 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406794 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL14645634 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL404495 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL407354 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL437806 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL403560 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL2278156 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL400817 | 0.93 | GPR35 (1.00) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL13961913 | 0.90 | GPR35 (0.70) | GPR35RARBMEN1ALDH1A1RARA | |
| SCHEMBL1363151 | 0.87 | GPR35 (0.68) | GPR35RARBMEN1ALDH1A1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| WO-2011081971-A2 | EGFR/VEGFR DUAL MODULATORS AND METHODS OF USING | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | GPR35 1127/4885RARB 1054/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.